Type 2 diabetes is now a global epidemic. However, drugs to treat diabetes are inadequate and generally have dose limiting side effects. We seek to address the epidemic with superior drugs based on a better understanding of the disease.
 
  MBX-102   MBX-8025   MBX-2044   MBX-2982   Additional Programs  
  Home > Pipeline > MBX-8025  
Targeting a Range of Lipid Disorders
Discussion around dyslipidemia often focuses on one element of the disease: hyperlipidemia, characterized by elevated levels of low-density lipoprotein (LDL, or “bad cholesterol”). While that condition is often effectively targeted by the statin drugs, many patients are unable to reach their LDL goal on a statin alone. There remains an opportunity for a drug that lowers LDL as a monotherapy or in combination with statins. There is an even greater need for a drug that also has a robust triglycerides-lowering effect while raising levels of high-density lipoprotein (HDL or “good cholesterol”).
MBX-8025 is being developed to treat a range of dyslipidemias, and early research suggests it may have a broader effect than statins, treating a number of the disorders that comprise metabolic syndrome, including increased levels of LDL, Apo B-100 (a form of cholesterol linked to atherosclerosis) and triglycerides, low levels of HDL, and increased insulin resistance and obesity.
MBX-8025 is a potent, selective PPAR-delta agonist that regulates fatty acid degradation, lipid storage/transport and insulin sensitivity. We have in-licensed the patents and the exclusive development and commercialization rights to MBX-8025 from Janssen Pharmaceutica NV, a Johnson & Johnson company.
We are now evaluating MBX-8025 in a Phase 2 study that is assessing the drug candidate’s effect on lipid levels as well as measures of insulin sensitivity and inflammation, both alone and in combination with a statin. Earlier studies of MBX-8025 showed that it improved lipid and blood glucose parameters in healthy adults.
Because MBX-8025 works through a novel pathway that differs from existing cholesterol medications, the potential also exists to use MBX-8025 as part of a combination therapy.